Inspire Medical Systems, Inc. (INSP) Stock Price & Analysis

Inspire Medical Systems, Inc. (INSP) closed at USD 71.11 on Friday, October 23, 2026, down 2.13% on the day. The US market is currently closed; this is not a live price.

The prior close was USD 72.66; the Oct 23, 2026 session ranged USD 68.46–72.75 on volume of 557,021 shares. Market capitalization is $2.06B, with a 52-week range of USD 38.91–147.03 (NYQ). Source: Nexqual, retrieved October 24, 2026 at 21:02 UTC.

Also available as compact Markdown for AI agents: nexqual.com/INSP.md

Key facts (INSP)

• Last four reported quarters (through Jun 30, 2026): revenue $899M, net income $135M (15.0% margin), free cash flow $117M (SEC filings).
• Valuation: P/E 15.2x (avg 62.3x at the last 2 fiscal year-ends).
• Insider open-market sales, last ~7 months: 4 Form 4 filings, $233K; 3 not under a Rule 10b5-1 plan ($202K); 0 by opportunistic insiders, 2 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Hold (mean 3.06 on a 1–5 scale) (18 analysts), mean target USD 68 (range 40–97).
• Total return with dividends: 1Y -8.3% vs S&P 500 +13.4%; 5Y -73.6% vs S&P 500 +76.9%.
• Next earnings: 2026-11-02, EPS estimate USD 0.09, revenue estimate $204M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (INSP)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (INSP)

P/E 15.2x · P/S 2.3x · P/FCF 17.6x · P/B 2.5x · FCF yield 5.70% · Earnings yield 6.57% · Buyback yield (TTM) 4.86%

P/E at fiscal year-ends: Dec 2025 18.9x, Dec 2024 105.8x.

Insider sales (SEC Form 4, open-market, last ~7 months) (INSP)

1 of 4 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (INSP)

Consensus Hold (mean 3.06 on a 1–5 scale), 18 analysts; mean target USD 68 (low 40, high 97).

Rating changes, last 120 days:

Total return (dividends reinvested) (INSP)

INSP revenue by region (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

INSP suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 13, 2026.

INSP company outlook (results filed Aug 3, 2026)

• “Guidance, and Strategic Growth Plan • Generated second quarter revenue of $200.6 million • Second quarter diluted EPS of $0.01; adjusted diluted EPS of $0.14 • Second quarter operating cash flow of $23.2 million • Announced strategic growth plan designed to unlock and redeploy $30 million for growth initiatives MINNEAPOLIS, MN - August 3, 2026 - Inspire Medical Systems, Inc.”

Quoted word-for-word from the SEC 8-K results press release.

INSP analyst estimates and revisions

INSP options: expected move

Options price a move of about ±17.9% (±$12.75) by Nov 20, 2026, which includes earnings on Nov 2, 2026. Over the last 8 reports the stock moved ±14% on average.

30-day implied volatility 67% vs 45% realized over the last 30 trading days. Put/call ratio (volume) 1. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 24, 2026 at 21:02 UTC)

Technical Analysis (INSP)

Nexqual's technical model rates INSP "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 24, 2026 at 21:02 UTC.

Analyst Ratings (INSP)

Wall Street analysts rate INSP "Hold" based on 18 analysts, with a mean price target of USD 68 (range USD 40–97), per Nexqual as of October 24, 2026 at 21:02 UTC.

Earnings (INSP)

Recent Earnings History

Source: Nexqual, October 24, 2026 at 21:02 UTC.

Financials & Fundamentals (INSP)

Source: Nexqual, October 24, 2026 at 21:02 UTC.

Financial Health Score (INSP)

Nexqual rates Inspire Medical Systems, Inc.'s overall financial health "Solid" across five dimensions, as of October 24, 2026 at 21:02 UTC.

Ownership (INSP)

Source: Nexqual, October 24, 2026 at 21:02 UTC.

Leadership (INSP)

Inspire Medical Systems, Inc. is led by Timothy P. Herbert, Founder, Chairman, CEO & President, per Nexqual as of October 24, 2026 at 21:02 UTC.

Major Backers & Investors (INSP)

Notable institutional backers of Inspire Medical Systems, Inc. include Wellington Management, Soleus Capital Management, L.P., AQR Capital Management, LLC, according to Nexqual as of October 24, 2026 at 21:02 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 24, 2026 at 21:02 UTC.

From Inspire Medical Systems, Inc.'s Latest SEC 10-K Filing (filed 2026-02-13)

Key Strengths & Strategy (as disclosed to the SEC)

• Our proprietary Inspire system is the first FDA, European Union ("EU") Regulation No. 2017/745 ("MDR" or "EU Medical Devices Regulation"), and Japan Pharmaceuticals and Medical Devices Agency-approved neurostimulation technology of its kind that provides a safe and effective treatment for patients with moderate to severe OSA.
• Our proprietary Inspire system is the first FDA-approved closed-loop neurostimulation technology that provides a safe and effective treatment for patients with moderate to severe OSA.
• Our proprietary algorithm tracks breathing patterns and the neurostimulator delivers electrical stimulation at the start of inspiration.
• We have developed the first FDA-approved neurostimulation technology that provides a safe and effective treatment for patients with moderate to severe OSA who have been confirmed to fail or cannot tolerate PAP treatments, such as CPAP.

Partnerships

• In 2007, we entered into an assignment and license agreement with Medtronic ("the Assignment and License Agreement") pursuant to which Medtronic assigned certain patents and trademarks to us and granted to us a worldwide, royalty-free license to certain other patents and technical information to make, use, import and sell products, and to practice methods in the field of electrical stimulation of the upper airway for the treatment of OSA ("the Field").

Legal & Regulatory Risks (Item 1A, quoted)

• Our products and operations are subject to extensive and changing laws, government regulation and oversight both in the U.S. and abroad, and our failure to comply with applicable requirements could harm our business.
• We may not receive the necessary approvals or certifications for our future products or expanded indications, and failure to timely obtain necessary approvals or certifications for our future products or expanded indications would adversely affect our ability to grow our business and our results of operations.
• The timing of FDA approval of a next generation product could have a significant impact on the carrying value of the inventory of our previous generation product, and therefore our results of operations.
• Failure to comply with post-marketing regulatory requirements could subject us to enforcement actions, including substantial penalties, and might require us to recall or withdraw a product from the market.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 21:02 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt